IMMU's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 2,433.3 -- higher than 98.25% of US-listed equities with positive expected earnings growth.
For IMMU, its debt to operating expenses ratio is greater than that reported by just 7.23% of US equities we're observing.
IMMU's price/sales ratio is 32,341.66; that's higher than the P/S ratio of 100% of US stocks.
If you're looking for stocks that are quantitatively similar to Immunomedics Inc, a group of peers worth examining would be URGN, GENE, NK, ADVM, and CYAD.
Immunomedics, Inc. focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases. The company was founded in 1982 and is based in Morris Plains, New Jersey.
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 6) * ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) * Akero Therapeutics Inc (NASDAQ: AKRO) * Amgen, Inc. (NASDAQ: AMGN) * Biondvax Pharmaceuticals Ltd - ADR (NASDAQ: BVXV) * Champions Oncology Inc (NASDAQ: CSBR) * Crispr Therapeutics AG (NASDAQ: CRSP) * Cytokinetics, Inc. (NASDAQ: CYTK) * DexCom, Inc. (NASDAQ: DXCM) * Eli Lilly And Co (NYSE: LLY) * Fate Therapeutics Inc (NASDAQ: FATE) * GENMAB A/S/S ADR (NASDAQ: GMAB) * Halozyme Therapeutics, Inc. (NASDAQ: HALO) * Hologic, Inc. (NASDAQ: HOLX) * Horizon Therapeutics PLC (NASDAQ: HZNP) * Illumina, Inc. (NASDAQ: ILMN) * Immunomedics, Inc. (NASDAQ: IMMU) (announced positive late-stage...